Title :

Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing enterobacteriaceae in children: a french prospective multicenter study

Author(s) :

Madhi, Fouad [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Jung, Camille [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Timsit, Sandra [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Levy, Corinne [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Biscardi, Sandra [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Lorrot, Mathie [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Grimprel, Emmanuel [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Hees, Laure [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Craiu, Irina [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Galerne, Aurelien [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Dubos, Francois [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Cixous, Emmanuel [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Hentgen, Veronique [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]
Bechet, Stéphane [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Bonacorsi, Stéphane [Auteur]
AP-HP Hôpital universitaire Robert-Debré [Paris]
Cohen, Robert [Auteur]
Groupe de Pathologie Infectieuse Pédiatrique [Paris] [GPIP]

Journal title :

PLoS One

Abbreviated title :

PLoS ONE

Volume number :

13

Pages :

e0190910

Publication date :

2018-01-01

ISSN :

1932-6203

English keyword(s) :

Mesh:Urinary Tract Infections/drug therapy
Mesh:Child
Mesh:Preschool
Mesh:Child
Mesh:Carbapenems/adverse effects
Mesh:Anti-Bacterial Agents/therapeutic use
Mesh:Anti-Bacterial Agents/adverse effects
Mesh:Amikacin/therapeutic use
Mesh:Enterobacteriaceae/drug effects
Mesh:Enterobacteriaceae/enzymology*
Mesh:Enterobacteriaceae Infections/drug therapy
Mesh:Enterobacteriaceae Infections/epidemiology
Mesh:Enterobacteriaceae Infections/microbiology*
Mesh:Female
Mesh:Fever/drug therapy
Mesh:Fever/microbiology
Mesh:France/epidemiology
Mesh:Humans
Mesh:Adolescent
Mesh:Infant
Mesh:Infant
Mesh:Newborn
Mesh:Male
Mesh:Microbial Sensitivity Tests
Mesh:Prospective Studies
Mesh:Risk Factors
Mesh:Urinary Tract Infections/epidemiology
Mesh:Urinary Tract Infections/microbiology*
Mesh:beta-Lactamases/biosynthesis*

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric ...
Show more >To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric Society set up an active surveillance network in pediatric centers across France in 2014. We prospectively analysed data from 2014 to 2016 for all children < 18 years old who received antibiotic treatment for FUTI due to ESBL-E in 24 pediatric centers. Baseline demographic, clinical features, microbiological data and antimicrobials prescribed were collected. 301 children were enrolled in this study. The median age was 1 year (IQR 0.02-17.9) and 44.5% were male. These infections occurred in children with history of UTIs (27.3%) and urinary malformations (32.6%). Recent antibiotic use was the main associated factor for FUTIs due to ESBL-E, followed by a previous hospitalization and travel history. Before drug susceptibility testing (DST), third-generation cephalosporins (3GC) PO/IV were the most-prescribed antibiotics (75.5%). Only 13% and 24% of children received amikacine alone for empirical or definitive therapy, respectively, whereas 88.7% of children had isolates susceptible to amikacin. In all, 23.2% of children received carbapenems in empirical and/or definitive therapy. Cotrimoxazole (24.5%), ciprofloxacin (15.6%) and non-orthodox clavulanate-cefixime combination (31.3%) were the most frequently prescribed oral options after obtaining the DST. The time to apyrexia and length of hospital stay did not differ with or without effective empirical therapy. We believe that amikacin should increasingly take on a key role in the choice of definitive therapy of FUTI due to ESBL-E in children by avoiding the use of carbapenems.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:55:47Z
2020-05-26T08:37:40Z